Arbios Systems, Inc.

WALTHAM, Mass., March 22 /PRNewswire-FirstCall/ -- Arbios Systems, Inc. (OTC Bulletin Board: ABOS - News) a biomedical device and cell therapy company developing proprietary liver assist products for the treatment of liver failure, today announced that the US Food and Drug Administration (FDA) has allowed the expansion of the number of clinical sites and increased the allowable number of patients in its IDE feasibility clinical trial for its SEPET(TM) liver assist device. Under the revised protocol, Arbios can include up to four clinical trial sites and to up to 20 liver failure patients with encephalopathy. The trial was previously limited to two sites and 15 patients. The Company further announced that the University of California at San Diego (UCSD) Medical Center will serve as an additional clinical site in the trial. UCSD joins Cedars Sinai Medical Center in Los Angeles and Albert Einstein Medical Center in Philadelphia as authorized clinical sites for this ongoing trial.

Comment - Expansion of sites in a clinical trial is never bad news. The list of clinical sites are A+. I would keep an eye on this one.